Trial Profile
A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multiple Center, Multiple-Dose Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Patients with Partial Onset Seizures (STAR 1)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Epilepsy
- Focus Therapeutic Use
- Acronyms STAR 1
- Sponsors Zynerba Pharmaceuticals
- 05 Dec 2017 Results of STAR 1 and STAR 2, presented at the 71st Annual Meeting of the American Epilepsy Society.
- 03 Dec 2017 Data through nine months of total exposure to ZYN002 (three months of treatment in STAR 1 and six months in STAR 2) presented in a Zynerba Pharmaceuticals Media Release.
- 03 Dec 2017 Status changed from active, no longer recruiting to completed, according to a Zynerba Pharmaceuticals media release.